Nevertheless, additional studies are required to investigate whether mutations less frequent in CMT genomes, such as ERBB2 amplifications, have similar biological or clinical implications as those in human breast cancers or whether they merely represent redundant alterations arising in the background of neutral mutations. This evidence concerns the gene ERBB2 and breast cancer.